1-10 of 10
Jeffrey A. Morgan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Candace L. Haddox, Michael J. Nathenson, Emanuele Mazzola, Jia-Ren Lin, Joanna Baginska, Allison Nau, Jason L. Weirather, Edwin Choy, Adrian Marino-Enriquez, Jeffrey A. Morgan, Gregory M. Cote, Priscilla Merriam, Andrew J. Wagner, Peter K. Sorger, Sandro Santagata, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1281–1292.
https://doi.org/10.1158/1078-0432.CCR-23-2250
Published: 01 April 2024
View article titled, Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Open the PDF for Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates in another window
Includes: Supplementary data
Journal Articles

Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance

Inga-Marie Schaefer, Matthew L. Hemming, Meijun Z. Lundberg, Matthew P. Serrata, Isabel Goldaracena, Ninning Liu, Peng Yin, Joao A. Paulo, Steven P. Gygi, Suzanne George, Jeffrey A. Morgan, Monica M. Bertagnolli, Ewa T. Sicinska, Adrian Mariño-Enríquez, Jason L. Hornick, Chandrajit P. Raut, George D. Demetri, Wen-Bin Ou, Sinem K. Saka, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A013.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A013
Published: 15 September 2022
View article titled, Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance
Journal Articles

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A. Morgan, Constance M. Barysauskas, Jillian Phallen, Olivia Triplett, Adrián Mariño-Enríquez, Andrew J. Wagner, George D. Demetri, Victor E. Velculescu, Cloud P. Paweletz, Jonathan A. Fletcher, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7287–7293.
https://doi.org/10.1158/1078-0432.CCR-19-2150
Published: 13 December 2019
View article titled, Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Open the PDF for Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors in another window
Includes: Supplementary data
Journal Articles

Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines

John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemer, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, Glenn Dranoff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3178–3186.
https://doi.org/10.1158/1078-0432.CCR-14-2932
Published: 14 July 2015
View article titled, Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
Open the PDF for Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines in another window
Journal Articles

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (21): 6020–6029.
https://doi.org/10.1158/1078-0432.CCR-13-0953
Published: 31 October 2013
View article titled, A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Open the PDF for A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

Richard Quek, Qian Wang, Jeffrey A. Morgan, Geoffrey I. Shapiro, James E. Butrynski, Nikhil Ramaiya, Tarsha Huftalen, Nicole Jederlinic, Judith Manola, Andrew J. Wagner, George D. Demetri, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 871–879.
https://doi.org/10.1158/1078-0432.CCR-10-2621
Published: 15 February 2011
View article titled, Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Open the PDF for Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors in another window
Journal Articles

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

George D. Demetri, Patricia Lo Russo, Iain R.J. MacPherson, Ding Wang, Jeffrey A. Morgan, Valerie G. Brunton, Prashni Paliwal, Shruti Agrawal, Maurizio Voi, T.R. Jeffry Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6232–6240.
https://doi.org/10.1158/1078-0432.CCR-09-0224
Published: 30 September 2009
View article titled, Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

George D. Demetri, Michael C. Heinrich, Jonathan A. Fletcher, Christopher D.M. Fletcher, Annick D. Van den Abbeele, Christopher L. Corless, Cristina R. Antonescu, Suzanne George, Jeffrey A. Morgan, Ming Hui Chen, Carlo L. Bello, Xin Huang, Darrel P. Cohen, Charles M. Baum, Robert G. Maki
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5902–5909.
https://doi.org/10.1158/1078-0432.CCR-09-0482
Published: 14 September 2009
View article titled, Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
Open the PDF for Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

George D. Demetri, Paolo G. Casali, Jean-Yves Blay, Margaret von Mehren, Jeffrey A. Morgan, Rossella Bertulli, Isabelle Ray-Coquard, Philippe Cassier, Monica Davey, Hossein Borghaei, Daniel Pink, Maria Debiec-Rychter, Wing Cheung, Stuart M. Bailey, Maria Luisa Veronese, Annette Reichardt, Elena Fumagalli, Peter Reichardt
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5910–5916.
https://doi.org/10.1158/1078-0432.CCR-09-0542
Published: 14 September 2009
View article titled, A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
Open the PDF for A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors in another window
Journal Articles

Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors

Jayesh Desai, Sridhar Shankar, Michael C. Heinrich, Jonathan A. Fletcher, Christopher D. Fletcher, Judi Manola, Jeffrey A. Morgan, Christopher L. Corless, Suzanne George, Kemal Tuncali, Stuart G. Silverman, Annick D. Van den Abbeele, Eric van Sonnenberg, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5398–5405.
https://doi.org/10.1158/1078-0432.CCR-06-0858
Published: 17 September 2007
View article titled, Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors
Open the PDF for Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors in another window